BioCentury
ARTICLE | Company News

Akarna, Allergan deal

September 26, 2016 7:00 AM UTC

Allergan acquired Akarna for $50 million up front and undisclosed development, regulatory and sales milestones tied to lead asset AKN-083, a farnesoid X receptor (FXR; NR1H4) agonist that is in pre...